Amgen details denosumab's cancer benefits

With a likely FDA approval for its blockbuster bone drug denosumab looming next month, Amgen researchers took to the stage at a Berlin conference to outline the therapy's benefits for breast cancer patients. The drug delayed skeletal deterioration in women with advanced breast cancer better than Novartis' Zometa, the data indicates. And the drug also delayed the worsening of bone pain in the comparison study. Amgen is already building a sales force for the drug, which is widely expected to gain official FDA approval. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.